Madiha Derouazi
Chief Tech/Sci/R&D Officer at AC IMMUNE SA
Net worth: 7 271 $ as of 2024-04-29
Profile
Madiha Derouazi is the founder and current Chief Executive Officer & Director of Amal Therapeutics SA, which is founded in 2012.
She is also currently the Chief Scientific Officer at AC Immune SA, where she started in 2024.
Dr. Derouazi has a graduate degree from the Technical University of Berlin and a doctorate degree from the Swiss Federal Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AC IMMUNE SA
0.00% | 2024-02-29 | 3,175 ( 0.00% ) | 7 271 $ | 2024-04-29 |
Madiha Derouazi active positions
| Companies | Position | Start |
|---|---|---|
| AC IMMUNE SA | Chief Tech/Sci/R&D Officer | 2023-12-31 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Founder | 2012-09-02 |
Former positions of Madiha Derouazi
| Companies | Position | End |
|---|
Training of Madiha Derouazi
| Technical University of Berlin | Graduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Private companies | 1 |
|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Madiha Derouazi